Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214200 | 0.82 | ULK1 (0.33) | PIK3CDULK1ATRPOLBAURKA | |
| SCHEMBL21606876 | 0.77 | PIK3CD (0.36) | PIK3CDKDM4EALDH1A1POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27573305 | 0.76 | PIK3CD (0.35) | PIK3CDAURKAKDRAURKB | |
| SCHEMBL22832019 | 0.74 | ABL1 (0.32) | — | |
| SCHEMBL22831886 | 0.73 | DYRK1A (0.38) | — | |
| SCHEMBL19837344 | 0.68 | AURKA (0.43) | PIK3CDULK1AURKAKDRAURKB | |
| SCHEMBL20088854 | 0.68 | NOS2 (0.39) | PIK3CDPOLB | |
| SCHEMBL21792331 | 0.68 | NOTUM (0.46) | KDM4EALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL503280 | 0.68 | IDO1 (0.43) | PIK3CDPOLB | |
| SCHEMBL6739131 | 0.68 | PIK3CD (0.45) | PIK3CDKDM4EALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-07 | — | — | US | disclosed |
| EP-3810598-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019244049-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244049-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | CBR3, HCRTR1, CYP4F11 | PIK3CD 4365/4885ULK1 4655/4885ATR 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.